Neglected Tropical Diseases Diagnosis Market Size, Share & Trends Analysis Report By Disease (Dengue, Chikungunya), By Diagnostic Method (Conventional, Molecular/Modern), By Service Type, By End Use, And Segment Forecasts, 2023 - 2030

Market Size & Trends

The global neglected tropical diseases diagnosis market size was valued at USD 6.32 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030. Growing awareness of neglected tropical diseases (NTDs) and increasing number of initiatives undertaken by the government are anticipated to fuel the market growth. For instance, inclusion of NTDs in the Sustainable Development Goals (SDG), a United Nations Development Program, as a global target is anticipated to fuel market growth. Furthermore, various initiatives being undertaken by WHO, such as road map 2030 for the elimination of NTDs, are expected to drive market growth during the forecast period.

In the wake of the COVID-19 pandemic, the neglected tropical disease (NTD) diagnosis witnessed a significant decline. WHO launched the Global Program to Eliminate Lymphatic Filariasis (GPELF) in 2000, which aims to stop the spread of infection and relieve the pain of those who have already been afflicted. However, according to the pulse survey conducted by WHO, as of early 2021, the neglected tropical disease program has faced disruptions in 44% of countries. Moreover, the high risk of transmission of SARS-CoV-2 infection has affected the public health approaches for NTDs. In countries with low health budgets, funds being shifted to tackle other diseases, and a shortage of funding from international partners and the foreign government has significantly impacted the growth of the market.

The NTD program has expanded its support to 31 countries in Asia, Latin America, and Africa. Besides, it has provided more than 2.6 billion treatments and leveraged more than USD 22.3 billion in donated medicines. Government organizations such as CDC and WHO collaborate with counties to improve existing public health services for NTDs. Moreover, in January 2021, the WHO introduced its roadmap for NTDs for the period 2021 to 2030. It is aimed to increase the prevention and control of neglected tropical diseases worldwide. Such initiatives undertaken by the government bodies are anticipated to drive the market growth during the forecast period.

Globally, several organizations initiated multiple programs, which contribute to rising in the awareness of NTDs, including the Global NTD Program by the Centers for Disease Control and Prevention, Global NTD Programs by the World Health Organization, NTD Program by the United States Agency for International Development, the United States Global Health Initiative. The primary focus of all these programs is on controlling or eliminating NTDs. For instance, in April 2023, WHO published 3 online resources with an aim to strengthen implementation of programs developed specifically for neglected tropical diseases. Similarly, the London Declaration was initiated to sustain, expand, and extend different programs to support & control guinea worm disease, leprosy, lymphatic filariasis, sleeping sickness, trachoma, schistosomiasis, and Chagas disease by 2020.

The increasing burden of NTDs is considered to be a major factor fueling the growth of the overall market during the forecast period. According to WHO estimates, more than 1.7 billion individuals, about one-fifth of the world’s population, mostly in lower-income and developing countries-required interventions for at least one NTD every year. Around 40% of the African region was affected by NTDs. These diseases are more prevalent among the poor population living in tropical environments and difficult-to-access areas. Countries such as Brazil, Yemen, India, Bangladesh, China, and some countries in Central & East Africa contribute the majority of NTD cases globally.

Disease Insights

Based on disease, soil-transmitted helminthiases dominated the market with a revenue share of 9.93% in 2022 owing to the increasing prevalence and high adoption of diagnostic tests. Moreover, the low false-positive rate of molecular diagnostics provides a competitive advantage over conventional and rapid tests. Furthermore, according to the WHO, as of January 2022, more than 1.5 billion people are infected with soil-transmitted helminth infections worldwide. The Kato-Katz technique is the WHO gold standard that is widely used to diagnose the intensity of STHs. Besides, neglected tropical diseases such as dengue, chikungunya, lymphatic filariasis, foodborne trematode infections, and others also held a significant share of the global market.

The Dracunculiasis segment is estimated to exhibit the fastest growth rate over 5.5% during the forecast period. It is a crippling parasitic infection on the verge of extinction, with 27 human cases registered in 2020. Out of these, 12 human cases of Guinea worm illness (dracunculiasis) were reported in Chad in 2020—a 75% decrease from 48 in 2019. In Ethiopia, 11 such cases have been documented, with one each in Angola, Cameroon South, Sudan, and Mali. The extension of disease and growing awareness among the population, and higher costs of the test may also contribute to the segment’s growth in terms of revenue.

Diagnostics Method Insights

The molecular/modern diagnostic segment dominated the market in 2022 with a revenue share of around 50.38%, which can be attributed to high usage rates of modern diagnostics. Moreover, the segment is anticipated to experience the fastest growth rate during the forecast period. An increase in R&D for molecular diagnostic techniques coupled with a rise in demand for point-of-care products is expected to boost the market expansion at a CAGR of 5.0% by 2030.

Factors taken into consideration while opting for various diagnostic methods include specificity, sensitivity, cost-effectiveness, and the availability of skilled personnel. Conventional diagnostic methods are based on microscopic & macroscopic identification of pathogens through gram stain, pathogen culturing, biochemical methods, and serology tests.

Relatively higher availability of conventional methods, compared to modern techniques, across many labs and clinics is a key factor that has enabled this segment to dominate in the market. However, these tests exhibit certain limitations relating to speed, timeline, and accuracy. Furthermore, rapid technological advances are compelling end-users to opt for molecular/modern methods over conventional methods.

Service Type Insights

Centralized service was the largest segment with market share of 60.79% in 2022 owing to high procedure volume and wide presence of ancillary support in terms of infrastructure and manpower. However, the PoC segment is likely to be the fastest-growing segment during the forecast period. Rising demand for bedside patient care due to the booming home healthcare market, technological advancements, and increasing market penetration are among the major factors driving the segment growth.

Furthermore, POC services provide quick results, allowing immediate diagnosis and better patient outcomes. Moreover, in 2017, the U.S. FDA approved the first POC test, “Chagas Detect Plus Rapid Test Kit” a 510K clearance. This POCT for Chagas disease has been developed by InBios International. Furthermore, in March 2023, Kephera Diagnostics received USD 3 billion grant from NIH for development of POC test for Chagas disease. Such achievements are anticipated to impact the growth of this segment positively throughout the forecast period.

End-use Insights

Clinical laboratory segment held the largest market share in terms of revenue with revenue share of 44.6% owing to high market penetration & procedure volumes and large number of laboratories in emerging & underdeveloped markets. Moreover, an increase in the number of initiatives undertaken by the government to provide various services, such as reimbursement for diagnostic tests, is another major factor anticipated to drive the market. However, the home healthcare segment is expected to grow at the fastest growth rate owing to the increasing adoption of point of care testing services.

Hospitals/Clinics segment held the second largest market share in 2022. Public health laboratories serve an important role in performing high-quality testing for NTDs and associated antimicrobial resistance. Moreover, the growing disease burden and rising healthcare expenditure may boost segment growth. In addition, the WHO guidelines for the management and eradication of diseases can be achieved through timely treatment and testing by hospitals & clinics.

Regional Insights

Asia Pacific held a 31.42% share of the neglected tropical diseases diagnosis market in 2022 due to the high disease burden of NTDs, increased healthcare expenditure, rapid technological advancements, proactive government initiatives, and a rise in customer awareness about the use of PCR tests in diagnosing NTDs.

Latin America is expected to show the fastest growth rate during the forecast period due to increased IVD product penetration and the high disease burden of NTDs in developing countries in the region. In addition, an increase in government spending, the presence of skilled healthcare professionals, and a rise in the focus of multinational diagnostic companies on the development of advanced & novel IVD products are among the factors likely to drive market growth in Latin America. However, low awareness about the prevention & treatment of infectious diseases in underdeveloped areas and the lack of favorable reimbursement policies are some of the key factors restraining market growth.

Recently, Argentina proposed reform in its healthcare system, stating that the controlling power of private pavers should be with the government. This may lead to affordable pricing of tests for the common population, leading to an increase in the demand for IVD instruments and reagents.

Key Companies & Market Share Insights

Key players are undertaking various strategic initiatives to increase their share in the market. New product development, collaborations, and partnerships are some such endeavors. For instance, in May 2023, Astellas Pharma Inc. announced commitment to support Global Health Innovative Technology Fund focusing on development of drugs, diagnostics, and vaccines to help combat various infectious diseases, including neglected tropical diseases. Some of the key players in the neglected tropical diseases diagnosis market include:

• F. Hoffmann-La Roche Ltd

• Abbott

• Thermo Fisher Scientific Inc.

• ZeptoMetrix

• InBios International, Inc.

• Genome Diagnostics Pvt. Ltd.

• Omega Diagnostics Group PLC

• Coris BioConcept

• DiaSys Diagnostic Systems GmbH

• Oscar Medicare Pvt Ltd.

Neglected Tropical Diseases Diagnosis Market Report Scope

Global Neglected Tropical Diseases Diagnosis Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global neglected tropical diseases diagnosis market report on the basis of disease, diagnostic method, service type, end-use, and region:

• Disease Outlook (Revenue, USD Million, 2018 - 2030)

  • Dengue

  • Chikungunya

  • Rabies

  • Leprosy

  • Buruli Ulcer

  • Yaws

  • Lymphatic Filariasis

  • Taeniasis/Cysticercosis

  • Foodborne Trematodiases

  • Echinococcosis

  • Chagas Disease (American Trypanosomiasis)

  • Dracunculiasis

  • African Trypanosomiasis

  • Soil-transmitted Helminth Infections

  • Onchocerciasis

  • Schistosomiasis

  • Scabies and Other Ectoparasites

  • Snakebite Envenoming

  • Leishmaniasis

• Diagnostic Method Outlook (Revenue, USD Million, 2018 - 2030)

  • Conventional Method

  • Molecular/Modern Method

• Service Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Centralized Service

  • POC Service

• End-Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Clinical Labs

  • Hospitals /Clinics

  • Home Healthcare

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

  • Asia Pacific

    • China

    • India

    • Indonesia

    • Malaysia

  • Latin America

    • Brazil

    • Colombia

    • Venezuela

  • Middle East and Africa (MEA)

    • Nigeria